Xellia expands global specialty anti-infective manufacturing

Denmark-based Xellia Pharmaceuticals, a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has held an official ground breaking ceremony for a new $25 million expansion at its Copenhagen site.

This site houses Xellia’s headquarters and is the company’s largest product manufacturing plant. Since 2013, Xellia is a wholly-owned by Novo Holdings A/S, which is also a major shareholder in Danish diabetes care giant Novo Nordisk (NOV: N).

Xellia’s Copenhagen site is responsible for manufacturing, stability testing and packaging of both sterile active pharmaceutical ingredients (APIs) and the finished dosage forms (FDFs) for anti-infectives such as vancomycin, and colistimethate sodium.